Clinical Trials on Hepatocellular Injury

Total 12551 results

Rennes University Hospital

Completed

Interest of Oxygenated Hypothermic Perfusion (PHO) in Preservation of Hepatic Grafts From Expanded Criteria Donors (PERPHO)

Hepatocellular Injury

France
Maastricht University Medical Center

Completed

Effect of Intermittent Pedicle Clamping on Hepatocellular Injury During Liver Surgery

Blood Loss | Hepatocellular Injury

Netherlands
University of Zurich

Completed

Hypothermic Oxygenated Perfusion (HOPE) of Human Liver Grafts

Hepatocellular Injury

Switzerland
University of Milan

Completed

Selection Criteria for Safe Hepatectomy for Hepatocellular Carcinoma

Hepatectomy | Cirrhosis | Hepatecellular Carcinoma

Italy
Assiut University

Completed

Immune Responses in Hepatocellular Carcinoma Patients After Treatment With Direct Acting Antiviral Drugs

Drug-Induced Liver Injury

Egypt
Ming Zhao

Approved for marketing

HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC

Hepatocellular Carcinoma | Injury; Blood Vessel, Hepatic, Artery

China
National Cancer Institute (NCI)

Completed

Tremelimumab With Chemoembolization or Ablation for Liver Cancer

Hepatocellular Carcinoma | Biliary Tract Neoplasms | Liver Cancer | Biliary Cancer | Heptocellular Cancer

United States
Chinese University of Hong Kong

Active, not recruiting

EUS Guided Cyanoacrylate Injection vs Endoscopic Variceal Band Ligation for Prevention of Rebleeding in Patients With Hepatocellular Carcinoma and Esophageal Variceal Bleeding (EUSgluevsVBL)

EUS Guided Cyanoacrylate Injection | Endoscopic Variceal Band Ligation | Hepatocelular Carcinoma | Esophageal Variceal Bleeding

Hong Kong
Charite University, Berlin, Germany

Recruiting

Hypothermic Oxygenated (HOPE) Versus Normothermic Machine Perfusion (NMP) in Human Liver Transplantation (HOPE-NMP)

Liver Transplant Disorder | Hepatocellular Injury

Germany
Roswell Park Cancer Institute
National Comprehensive Cancer Network

Completed

Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Unresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditions

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditions

United States
Roswell Park Cancer Institute
Merck Sharp & Dohme LLC

Active, not recruiting

Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer

Advanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Unresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditions

United States, Canada, Puerto Rico
Edward Kim
Bristol-Myers Squibb; National Cancer Institute (NCI)

Terminated

BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer

Advanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular Carcinoma

United States
Northwestern University
Bristol-Myers Squibb; National Cancer Institute (NCI)

Completed

Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer

Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; American Society of Clinical Oncology; Radiological... and other collaborators

Withdrawn

Y-90 Versus SBRT for Inoperable HCC

Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma AJCC v8 | Stage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Stage... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma...

United States
Robin Kate Kelley
Bristol-Myers Squibb; Bayer

Active, not recruiting

Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer

Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular...

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Withdrawn

Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Locally Advanced Hepatocellular Carcinoma
Emory University
National Cancer Institute (NCI); Eisai Co., Ltd.

Recruiting

Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

Unresectable Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC... and other conditions

United States
Mary Feng, MD
AstraZeneca

Recruiting

Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for Liver Cancer After Progression on PD-1 Inhibition

Advanced Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer

Advanced Adult Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma...

United States
AstraZeneca
Hospital Israelita Albert Einstein

Recruiting

Brazilian Reality of Hepatocellular Carcinoma (BRA-HEP)

Hepatocellular Carcinoma | Hepatocellular Carcinoma by BCLC Stage | Hepatocellular Carcinoma Stage I | Hepatocellular Carcinoma Stage III | Hepatocellular Carcinoma Stage II

Brazil
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC; Highlight Therapeutics

Terminated

BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer

Advanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Refractory Hepatocellular Carcinoma

United States
M.D. Anderson Cancer Center

Recruiting

Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer

Stage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Resectable Hepatocellular Carcinoma | Stage I Hepatocellular Carcinoma AJCC v8 | Stage IA Hepatocellular Carcinoma AJCC v8

United States
Mayo Clinic

Recruiting

68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer

Advanced Hepatocellular Carcinoma | Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8

United States
Sirtex Medical
Bright Research Partners

Recruiting

Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients (DOORwaY90)

Unresectable Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | BCLC Stage A Hepatocellular Carcinoma

United States
University of Southern California
National Cancer Institute (NCI)

Completed

MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer

Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Adult Hepatocellular Carcinoma | BCLC Stage B Adult Hepatocellular Carcinoma | BCLC Stage C Adult Hepatocellular Carcinoma | BCLC Stage D Adult Hepatocellular Carcinoma | Localized Resectable Adult Liver... and other conditions

United States
Ohio State University Comprehensive Cancer Center
Varian Medical Systems

Completed

Stereotactic Body Radiation Therapy and Transarterial Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Child-Pugh Class A | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Child-Pugh Class B

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Suspended

Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer

Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma AJCC v8 | Unresectable Fibrolamellar...

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer

Recurrent Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Stage I Hepatocellular Carcinoma AJCC v8

United States
University of Washington
Exelixis

Terminated

Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer

Advanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Pembrolizumab With or Without Elbasvir/Grazoprevir and Ribavirin in Treating Patients With Advanced Refractory Liver Cancer

Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Hepatitis C Infection | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 | Stage IIIA Hepatocellular... and other conditions

United States
Ethicon, Inc.

Completed

Study to Evaluate the Safety and Effectiveness of Microwave Ablation in Patients With Hepatocellular Carcinoma in Korea

Carcinoma, Hepatocellular | Hepatocellular Carcinoma | Hepatocellular Cancer | Cancer, Hepatocellular

Korea, Republic of
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer

Recurrent Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Refractory Liver Carcinoma

United States
Replimune Inc.
Roche Pharma AG

Not yet recruiting

RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC

Recurrent Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | Locally Advanced Hepatocellular Carcinoma

United States, United Kingdom, France, Germany, Greece
Jiping Wang, MD, PhD
AstraZeneca; Sirtex Medical

Recruiting

SIRT With Tremelimumab and Durvalumab for Resectable HCC

Hepatocellular Carcinoma | Hepatocellular Cancer | Resectable Hepatocellular Carcinoma

United States
Amgen

Completed

A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer

Advanced Hepatocellular Carcinoma | Inoperable Hepatocellular Carcinoma
Asan Medical Center
Seoul National University Hospital; Hanyang University; Soon Chun Hyang University

Recruiting

Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion (ALERT-HCC)

Hepatocellular Carcinoma | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Stage IV

Korea, Republic of
Stanford University

Completed

B-mode Ultrasound Imaging in Detecting Early Liver Cancer

Fibrosis | Cirrhosis | Stage I Hepatocellular Carcinoma | Stage II Hepatocellular Carcinoma | Early Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

Hepatocellular Carcinoma | Hepatocellular Cancer | Metastatic Hepatocellular Carcinoma

United States
Kaohsiung Medical University Chung-Ho Memorial...
Kaohsiung Medical University

Recruiting

Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment

Cholangiocarcinoma, Intrahepatic | Hepatocellular Carcinoma Stage IIIB | Cholangiocarcinoma; With Hepatocellular Carcinoma | Hepatocellular Carcinoma Stage IV

Taiwan
National Cancer Institute (NCI)

Recruiting

GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma | Hepatocellular Cancer | Metastatic Hepatocellular Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer

Advanced Adult Hepatocellular Carcinoma | Advanced Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma | BCLC Stage B Adult Hepatocellular Carcinoma | BCLC Stage C Adult Hepatocellular Carcinoma

United States

Clinical Trials on Hepatocellular Injury

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations